RGT-61159

Rgenta Therapeutics Inc · Phase 1 active Small molecule

At a glance

Generic name	RGT-61159
Sponsor	Rgenta Therapeutics Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RGT-61159 CI brief — competitive landscape report
RGT-61159 updates RSS · CI watch RSS
Rgenta Therapeutics Inc portfolio CI